NDAORALTABLET
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
4/8 — Partial
SEGLENTIS (celecoxib; tramadol hydrochloride) by Kowa Pharmaceuticals is 12. First approved in 2021.
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEGLENTIS is a fixed-dose combination of celecoxib (a selective COX-2 inhibitor) and tramadol hydrochloride (an opioid analgesic) approved for moderate to severe pain management. The combination leverages celecoxib's anti-inflammatory and analgesic properties via prostaglandin synthesis inhibition paired with tramadol's central nervous system pain modulation. This oral tablet formulation targets patients requiring multimodal analgesia beyond monotherapy efficacy.
$0.664MPart D
Peak4.6 years to LOEProduct is in peak commercial phase with established baseline claims; team focus likely on market penetration and formulary positioning in competitive pain management segment.
Mechanism of Action
12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Celecoxib has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of…
Worked on SEGLENTIS at Kowa Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.